Pharma Pulse: Commercial Risks of the NDC-12 Transition and FDA Approval of Avlayah for Hunter Syndrome

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• First, experts are highlighting potential commercial risks stemming from the industry's upcoming 2033 transition to a uniform 12-digit NDC format. Modeling warns of thousands of "zero-prefix collisions" where different drug products could share identical identifiers in automated systems. These errors threaten to trigger widespread PBM claim rejections, disrupt patient hub enrollments, and corrupt market intelligence data, leading to significant revenue leakage for teams that fail to update their systems early.
• Next, the FDA has granted accelerated approval to Avlayah, the first therapy engineered to cross the blood-brain barrier for the treatment of Hunter syndrome. This breakthrough marks the community's first new treatment option in nearly 20 years. The approval was based on a 91% reduction in a key disease biomarker, providing a new standard for addressing neurological decline, though continued approval is contingent on a confirmatory trial.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.